Viloxazine: A New Non-Stimulant Treatment for Attention-Deficit/Hyperactivity Disorder (ADHD)

• Váldodahkkit: Wiktoria (Dahkki), Anna Greguła (Dahkki), Karol Stachyrak (Dahkki), Dawid Mika (Dahkki), Aleksandra Kłos (Dahkki), Kamila Turek (Dahkki), Maciej Lambach (Dahkki), Mateusz Pawlicki (Dahkki), Aleksandra Mazurek (Dahkki), Bartosz Mazur (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Kazimierz Wielki University, 2024-02-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Introduction Viloxazine is an antidepressant medication classified as an SNRI (serotonin and norepinephrine reuptake inhibitor). In April 2021, it received FDA approval in the United States for the treatment of ADHD in children aged 6 to 17. Subsequently, in May 2022, it was also approved for the tr...